Clinical Scorecard: Evaluation of Lumboperitoneal Shunt Versus Ventriculoperitoneal Shunt in Managing Hydrocephalus Due to Leptomeningeal Metastasis in Patients with Non-Small Cell Lung Cancer

At a Glance

Key Highlights

• Leptomeningeal metastasis is a rare, aggressive complication of advanced NSCLC with poor prognosis.
• LM-associated hydrocephalus occurs in 1%–5% of LM patients, causing neurological symptoms due to raised ICP.
• LP shunt surgery is a less invasive alternative to VP shunt with potential benefits including lower complication risk and avoidance of general anesthesia.

Guideline-Based Recommendations

Diagnosis

• Confirm LM diagnosis using gadolinium-enhanced brain MRI, CSF cytology or meningeal biopsy, and clinical signs per EANO-ESMO guidelines.
• Classify LM based on MRI enhancement patterns and cytology results (types 1A to 2D).
• Diagnose hydrocephalus clinically (headache, nausea, cognitive decline) and radiologically (ventricular enlargement).

Management

• Consider VP shunt or endoscopic third ventriculostomy to relieve increased ICP in LM-associated hydrocephalus.
• LP shunt surgery is a viable alternative for communicating hydrocephalus, especially in patients unsuitable for general anesthesia.
• Palliative care or lumbar drainage may be options when surgery is contraindicated.

Monitoring & Follow-up

• Monitor neurological symptoms and imaging findings post-shunt surgery to assess ICP control and shunt function.
• Regular follow-up imaging and clinical evaluation to detect shunt complications or hydrocephalus progression.

Risks

• VP shunt surgery involves risks related to ventricular catheter insertion through brain tissue.
• LP shunt may reduce surgical risks but requires careful patient selection to exclude obstructive hydrocephalus.
• Poor patient condition may limit surgical options and affect prognosis.

Patient & Prescribing Data

Adults with NSCLC and confirmed LM-associated communicating hydrocephalus eligible for surgical intervention

LP shunts may offer safer, less invasive management with comparable effectiveness to VP shunts; however, evidence is limited and further comparative studies are needed.

Clinical Best Practices

• Use multidisciplinary evaluation including oncology and neurosurgery specialists to determine surgical eligibility.
• Follow EANO-ESMO guidelines for LM diagnosis and classification to guide treatment decisions.
• Select shunt type based on hydrocephalus subtype, patient condition, and surgical risk profile.
• Ensure thorough preoperative assessment and postoperative monitoring to optimize outcomes.

References

• EANO-ESMO Guidelines on Leptomeningeal Metastasis
• Clinical Features and Management of Leptomeningeal Metastasis
• Comparative Studies of LP and VP Shunt Surgeries